Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis

• Published in: Multiple sclerosis and related disorders Vol. 17; pp. 151 - 153
• Main Authors: Šega-Jazbec, Saša, Barun, Barbara, Horvat Ledinek, Alenka, Fabekovac, Višnja, Krbot Skorić, Magdalena, Habek, Mario
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2017
• Subjects: Administration, Intravenous; Administration, Oral; Adult; Alemtuzumab; Alemtuzumab - administration & dosage; Alemtuzumab - adverse effects; Anti-Inflammatory Agents - administration & dosage; Disability Evaluation; Female; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - adverse effects; Infusion associated reactions; Male; Methylprednisolone - administration & dosage; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Retrospective Studies; Time Factors; Treatment Outcome; Infusion associated reactions; Multiple sclerosis; Alemtuzumab
• ISSN: 2211-0348; 2211-0356
• DOI: 10.1016/j.msard.2017.07.019

Infusion-associated reactions (IARs) occur in >90% patients with multiple sclerosis (MS) treated with alemtuzumab. We aimed to study the frequency of IARs at 2 sites using 5 days of steroids (1g/day of IV methylprednisolone), but otherwise distinct protocols. This was retrospective chart review of 38 consecutive MS patients who were treated with alemtuzumab from June 2015 till February 2017 at Department of Neurology, University Hospital Center Zagreb, Croatia and Department of Neurology, University Medical Center Ljubljana, Slovenia. Seventeen patients (44.7%) did not experience IARs. Skin reactions and fever were the most common IARs attributed to alemtuzumab infusions and they were most frequent on Day 5 and Day 1, respectively. We have observed significant differences in the occurrence of fever (p = 0.005) depending on the site of alemtuzumab administration which could be explained by different antipyretics used; fever was absent in the Slovenian cohort because high dose intravenous metamizole was administered. Two out of 9 treatment naïve, and 19 out of 29 patients who previously received immunomodulatory treatment had IARs (χ2 = 5.208, p = 0.022). Modified premedication scheme consisting of 1g/day of IV methylprednisolone throughout all 5 days of alemtuzumab treatment may reduce overall IARs. Intravenous administration of antipyretics may work better than oral administration. •Skin reactions and fever were the most common IARs attributed to alemtuzumab infusions.•Modified premedication scheme may reduce overall IARs associated with alemtuzumab.•Intravenous compared to oral administration of antipyretics significantly reduces the occurrence of fever.